New COVID Variant BA.3.2 Spreading in the U.S.: Symptoms, Vaccine Impact, and What Experts Say
A new COVID variant called BA.3.2, sometimes nicknamed the “Cicada” variant, is drawing attention from health experts as it begins appearing in several parts of the United States and other countries.
Researchers say the variant contains more than 70 mutations in its spike protein, which could make it better at spreading and potentially help it partly evade immunity from vaccines or previous infections.
However, early data suggests that the severity of illness does not appear higher than other recent COVID variants, though researchers are still monitoring the situation closely.
What Is the BA.3.2 COVID Variant?
BA.3.2 is a subvariant of the Omicron coronavirus lineage. Scientists first detected it in South Africa in 2024, and it later spread to several countries including the U.S., Germany, and Australia.
Key points about BA.3.2:
- A new branch of the Omicron variant
- Contains 70–75 spike protein mutations
- First detected in South Africa
- Currently labeled a “variant under monitoring” by the WHO
- Found in wastewater and clinical samples across multiple U.S. states
Where Has the Variant Been Detected?
Scientists identified BA.3.2 through wastewater surveillance, traveler testing, and clinical samples.
U.S. States Reporting Detection
| Region | Status |
|---|---|
| California | Detected |
| Florida | Detected |
| New York | Detected |
| Texas | Detected |
| Pennsylvania | Detected |
| Illinois | Detected |
| Michigan | Detected |
| More than 20 additional states | Surveillance detection |
Researchers believe the variant may already be more widespread than confirmed cases suggest, because testing and genomic tracking remain limited in many areas.
Common Symptoms of the BA.3.2 Variant
The symptoms of BA.3.2 are similar to other Omicron variants and often resemble cold or flu symptoms.
Most Reported Symptoms
- Fever
- Persistent cough
- Sore throat
- Runny or blocked nose
- Fatigue
- Body aches
- Headache
- Loss of smell or taste (less common)
- Sneezing or nasal congestion
Symptoms typically affect the upper respiratory system, similar to many recent COVID strains.
Vaccine Effectiveness Against BA.3.2
Early laboratory studies suggest that the variant may partially evade antibodies produced by current vaccines because of its spike protein mutations.
However, experts stress several important points:
- Current vaccines still offer protection against severe illness
- Research on real-world vaccine effectiveness is ongoing
- Updated vaccine formulations may be considered in the future
The 2025–2026 mRNA COVID vaccine performed well against dominant variants but showed lower antibody neutralization against BA.3.2 in lab studies.
Early Case Information
| Category | Details |
|---|---|
| Hospitalized patients | Older adults with existing health conditions |
| Child patient | Mild illness, outpatient care |
| Fatalities | None reported in early cases |
| Severity | Similar to other Omicron infections |
Health experts emphasize that early hospital detections do not necessarily mean the variant causes more severe disease.
Key Takeaways
- BA.3.2 is a new Omicron subvariant currently being monitored by scientists.
- The strain contains many mutations that could help it spread more easily.
- It has been detected in multiple U.S. states and several countries.
- Early research suggests no evidence yet of more severe illness.
- Vaccines may be slightly less effective against infection but still protective against serious disease.
The BA.3.2 COVID variant is an emerging strain that scientists are closely watching. While its high number of mutations raises questions about vaccine protection and transmission, current evidence suggests it behaves similarly to other recent Omicron variants.
Public health experts recommend continuing vaccination, testing, and monitoring as researchers gather more data about this new variant.
